HealthDay News — Individuals previously infected with SARS-CoV-2 infection have antibody responses to one dose of the BNT162b2 (Pfizer-BioNTech) mRNA vaccine that are comparable to those of infection-naive individuals receiving 2 doses, according to a study published online April 1 in Nature Medicine.

Joseph E. Ebinger, MD, from the Cedars-Sinai Medical Center in Los Angeles, and colleagues enrolled 1090 health care workers from an academic medical center in Southern California who received BNT162b2 mRNA vaccine. Antibody levels were measured at 3 time points: before or up to 3 days after dose 1, within 7 to 21 days after dose one, and within 7 to 21 days after dose 2.

The researcher found that for individuals with prior SARS-CoV-2 infection (35 individuals), spike-specific immunoglobulin G antibody levels and angiotensin-converting enzyme 2 antibody binding inhibition responses elicited by a single vaccine dose were similar to those seen after 2 doses of vaccine in 228 individuals without prior infection. Postvaccine symptoms were experienced more often by individuals with previous SARS-CoV-2 infection than infection-naive individuals after dose one (36.8 vs 25.0%), but there was no difference between the groups in postvaccine symptoms after dose two (51.3 vs 58.7%).

“It appears that a single booster dose given to previously infected individuals offers the same benefit as 2 doses given to people without prior infection,” a coauthor said in a statement.

Continue Reading

Abstract/Full Text